The total number of records retrieved from this search are 28. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_951	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result70% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_952	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result90% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_953	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_954	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_983	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result100% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_984	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result100% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_985	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result100% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_986	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result70% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1087	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1088	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1089	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1751	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1752	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1753	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1754	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1755	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1756	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_1757	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line7.6E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCell cycle arrest at G2 phase and induction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID20087864
IDOV_2883	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2884	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result42% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2885	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result38% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2886	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineNeuroblastoma cell line	Cell lineIMR-32	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_4206	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration1 MOI	In-vitro result3 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4213	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.01 MOI	In-vitro result2 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4214	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.1 MOI	In-vitro result2 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_4215	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapanese cancer research resource bank	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration1 MOI	In-vitro result2 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectIncreased expression of Bcl-2 and Bcl-xL expression	Clinical trialNA	PMID26298056
IDOV_5620	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration41 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5840	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman neuroblastoma cell line	Cell lineIMR-32	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration41 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578